{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["FOLFIRINOX"]],"indication":"resectable pancreatic cancer","name":"NEPAFOX","nct_id":"NCT02172976","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nepafox-nct02172976. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Oxaliplatin 85mg/m², Irinotecan 180mg/m², 5-FU 400mg/m² Bolus i.v., 5-FU continuous Infusion 2400 mg/m² Natriumfolinate 400mg/m² 46h d1; qd15 6 cycles pre- and 6 cycles post- surgery","label":"FOLFIRINOX","type":"EXPERIMENTAL"},{"description":"Gemcitabine 1000 mg/m² d1, d8, d15; qd 29; 6 cycles after surgery","label":"Gemcitabine","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2020-05","type":"ACTUAL"},"conditions":["Resectable Prancreas Carcinoma"],"enrollment":{"count":40,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"},{"name":"5-Fluorouracil","otherNames":[],"type":"DRUG"},{"name":"Irinotecan","otherNames":[],"type":"DRUG"},{"name":"Natriumfolinate","otherNames":[],"type":"DRUG"}],"last_update":"2020-09-02","lead_sponsor":"Krankenhaus Nordwest","official_title":"Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer","overall_status":"COMPLETED","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2020-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"median overall survival","timeFrame":"From date of randomization until the date of death from any cause assessed up to 24 months"}],"references":[],"start_date":{"date":"2014-11"},"study_type":"INTERVENTIONAL","title":"Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma","url":"https://clinicaltrials.gov/study/NCT02172976"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nepafox-nct02172976"}